Investigational drug · Phase 2
mesenchymal stem cell
Also called: umbilical cord derived MSCs
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for AIDS, Ischemic Heart Disease, Osteoarthritis.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
1,454
Any phase or sponsor naming "mesenchymal stem cell"
First trial start
2023
Dec 10, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "mesenchymal stem cell", any sponsor or status.
Conditions studied
As listed on its trial records.
- AIDS
- Ischemic Heart Disease
- Osteoarthritis
Approved drugs for the same conditions: Osteoarthritis · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "mesenchymal stem cell" as an intervention, largest first.
Thomas Advanced Medical LLCIndustry
NCT04684602 · 5,000 participants (planned) · Start Jul 9, 2020 · Primary completion Jul 9, 2030
Drug: PrimePro™/ PrimeMSK™ · For: Autoimmune Diseases; Cardiovascular Disorders; Diabetes Complications and 8 more
Sites: Culver City, California
- Njinsky Ambispective Cellular Product Safety and Outcomes RegistryNot yet recruiting
Njinsky Medical CentreAcademic, hospital or other
NCT07941544 · 1,200 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 30, 2030
Drug: Umbilical Cord Mesenchymal Stem Cells; Stromal Vascular fraction · For: Retinitis Pigmentosa (RP); Autism Disorder; Diminished Ovarian Reserve and 3 more
Sites: Lahore, Pakistan
- Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)Pivotal-lookingRecruiting
Direct Biologics, LLCIndustry
NCT05354141 · 970 participants (planned) · Start Jul 1, 2022 · Primary completion Nov 30, 2027
Drug: ExoFlo · For: Acute Respiratory Distress Syndrome; ARDS
Sites: Phoenix, Arizona; Little Rock, Arkansas; Davis, California · 32 sites in all
- Long Term Follow up Mesenchymal Stem Cell Therapy for Patients Virus-related Liver CirrhosisPivotal-lookingCompleted
Ukraine Association of BiobankAcademic, hospital or other
NCT05080465 · 700 participants · Start Dec 2, 2018 · Primary completion Oct 7, 2024
Drug: Autologous BM MSC · For: Liver Cirrhosis
Sites: Kharkiv, Ukraine
UNICEFAcademic, hospital or other
NCT04492501 · 600 participants · Start Apr 1, 2020 · Primary completion Jul 20, 2020
Drug: Convalescent Plasma; Tocilizumab and 2 more · For: Covid19; Cytokine Release Syndrome; Critical Illness and 1 more
Sites: Rawalpindi, Pakistan
Stem Cells ArabiaAcademic, hospital or other
NCT02641769 · 600 participants (planned) · Start Jan 2014 · Primary completion Jun 2030
Drug: Stem Cell Transplantation · For: Non-obstructive Azoospermia
Sites: Amman, Jordan
- A Study to Investigate the Effectiveness, Safety, and Tolerability of MAG200 Solution for Intra-articular Injection Compared With Placebo in Participants Aged 35 to 75 Years of Age With Symptomatic Osteoarthritis of the Knee.Pivotal-lookingNot yet recruiting
Magellan Stem CellsIndustry
NCT07106229 · 573 participants (planned) · Start Nov 2025 · Primary completion Feb 2028
Drug: allogeneic human adipose-derived mesenchymal stem cells · For: Knee Osteoarthristis
- Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart FailurePivotal-lookingCompleted
Mesoblast, Inc.Industry
NCT02032004 · 565 participants · Start Mar 3, 2014 · Primary completion Jan 30, 2020
Drug: Rexlemestrocel-L · For: Chronic Heart Failure
Sites: Birmingham, Alabama; Gilbert, Arizona; Mesa, Arizona · 59 sites in all
- Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee OsteoarthritisPivotal-lookingRecruiting
Wuxi Cellular Biopharmaceutical Group Ltd.Industry
NCT06570291 · 520 participants (planned) · Start Feb 28, 2025 · Primary completion Dec 2026
Drug: Mesenchymal Stem Cells; Sodium Hyaluronate Injection · For: Knee Osteoarthritis
Sites: Shanghai, China · 2 sites in all
- Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)Pivotal-lookingCompleted
Emory UniversityAcademic, hospital or other
NCT03818737 · 475 participants · Start Mar 28, 2019 · Primary completion May 31, 2022
Drug: Bone Marrow Derived MSCs; Adipose-derived MSCs and 2 more · For: Osteoarthritis
Sites: Gulf Breeze, Florida; Atlanta, Georgia; Durham, North Carolina · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Spatial mechanopriming of multicellular interfaces drives cytoskeletal-to-nuclear remodeling to boost therapeutic efficacy of stem cells.
Bayaraa O, Lee NH, Kim SH, et al. · Bioact Mater 2027
- Dynamic tensile conditioning of mesenchymal stem cell-laden auxetic scaffolds for enhanced YAP-dependent miR-30 enrichment in extracellular vesicles for pulmonary fibrosis therapy.
Chen JX, Ho CC, Lin YH, et al. · Biomaterials 2027
- Micellar LYTAC-engineered bionic coatings abrogate RANK-dependent osteocatabolism and boost fibrillogenesis-mimetic mineral accretion for empowering osteoporotic osseointegration.
Zhao Y, Zhou J, He Y, et al. · Bioact Mater 2027
- PEOT/PBT - βTCP composites containing zinc, zinc and copper, and zinc and cobalt induce extracellular matrix deposition upon intramuscular implantation in a mini-pig model.
Nikody M, Li J, Koper DC, et al. · Biomaterials 2027
- The miR-6538 in extracellular vesicles derived from lycorine-pretreated mesenchymal stem cells enhances therapeutic efficacy in rheumatoid arthritis.
Zheng W, Xu X, Yang C, et al. · Biomaterials 2027
- Anti-inflammatory and early osteogenic potential of a 96% ethanol extract of Drynaria bonii.
Tai DC, Trinh PTN, Nhut KDM, et al. · J Ethnopharmacol 2027
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.